Trial Profile
A Presurgical Study To Evaluate Molecular Changes That Occur In Human Non-Small Cell Lung Cancer Tissue After Short Term Exposure To PF-00299804.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 21 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 21 Jun 2012 Actual patient number is 22 according to ClinicalTrials.gov.